Updates are available Correction dated 2025-11-28
Click to view Correction: https://doi.org/10.1007/s12325-025-03446-7
-
Authors
Artime, Esther
Spaepen, Erik
Zimner-Rapuch, Sarah
Lampropoulou, Anastasia
Adam, Atif
Lin, Xiaoyu
Shang, Mengyuan
Seager, Sarah
Le Roux, Carel W.
Dicker, Dror
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 29 July 2025
First Online: 19 August 2025
Change Date: 28 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-025-03446-7
Declarations
:
: Esther Artime and Sarah Zimner-Rapuch are employees and minor shareholders of Lilly and Company. Anastasia Lampropoulou was an employee and minor shareholder of Eli Lilly and Company at the time the work was conducted and is a current employee and minor shareholder of Novartis. Erik Spaepen is an external consultant of Eli Lilly and Company. Carel Le Roux has received consulting fees for advisory board participation from Eli Lilly, NovoNordisk, Johnson & Johnson, Boehringer Ingelheim, GI Dynamics, Herbalife, Altimmune, Irish Life Health, Roche and AstraZeneca; speaker fees from NovoNordisk, Herbalife, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Rhythm Pharmaceuticals and Currax Pharmaceuticals; support for travel to/attending meetings from NovoNordisk, Herbalife, Johnson & Johnson, Eli Lilly and Boehringer Ingelheim; institutional grants from the Irish Research Council, Health Research Board, Science Foundation Ireland, and Anabio; and holds stock or stock options in Keyron and Beyond BMI. Dror Dicker has received royalties or licenses, consulting fees, speaker fees, and support for travel to/attending meetings from NovoNordisk, Eli Lilly and Boehringer Ingelheim; institutional grants from NovoNordisk and Eli Lilly; and institutional provision of goods (equipment, materials, drugs, etc.)/services from NovoNordisk. He has participated in advisory boards for NovoNordisk, Eli Lilly and Boehringer Ingelheim. Atif Adam, Xiaoyu Lin, Mengyuan Shang, and Sarah Seager have no conflict of interest to declare.
: All analyses performed in this study were conducted in accordance with Data Use Agreement terms as specified by the data owners. For the databases for France, Germany, Italy, the UK, Australia, and Japan, there was no Institutional Review Board applicable to the usage and dissemination of the results of this study or required registration of the protocol with additional ethics oversight. For the database for Spain LPD, the Ethics Committee of the Hospital Clinic de Barcelona (Spain) reviewed and approved the protocol.
